A revised international prognostic score system for Waldenström’s macroglobulinemia

Efstathios Kastritis, Pierre Morel, Alain Duhamel, Maria Gavriatopoulou, Marie Christine Kyrtsonis, Eric Durot, Argiris Symeonidis, Kamel Laribi, Evdoxia Hatjiharissi, Loic Ysebaert, Amalia Vassou, Nikolaos Giannakoulas, Giampaolo Merlini, Panagiotis Repousis, Marzia Varettoni, Euridyki Michalis, Bénédicte Hivert, Michalis Michail, Eirini Katodritou, Evangelos Terpos & 2 others Veronique Leblond, Meletios A. Dimopoulos

Research output: Contribution to journalArticle

Abstract

A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in the chemoimmunotherapy era. We developed a revised system based on data from 492 symptomatic patients with at least 3 years and a median of 7 years of follow up while an independent validation cohort included 229 symptomatic patients. We identified age (≤65 vs 66–75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin <3.5 gr/dl, and LDH ≥ 250 IU/L (ULN < 225) to stratify patients in five different prognostic groups and identify a very-low risk as well as a very-high risk group with a 3-year WM-related death rate of 0, 10, 14, 38, and 48% (p < 0.001) and 10-year survival rate of 84, 59, 37, 19, and 9% (p < 0.001). We evaluated this staging system separately in patients >65 years and <65 years, according to the reason for initiation of treatment, among patients receiving frontline rituximab or in patients treated primarily without rituximab. With further validation before clinical use, this revised IPSSWM could improve WM patient risk stratification, is easily available and may be used in the everyday practice to provide prognostic information.

Original languageEnglish
JournalLeukemia
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Waldenstrom Macroglobulinemia
Serum Albumin
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kastritis, E., Morel, P., Duhamel, A., Gavriatopoulou, M., Kyrtsonis, M. C., Durot, E., ... Dimopoulos, M. A. (2019). A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia. https://doi.org/10.1038/s41375-019-0431-y

A revised international prognostic score system for Waldenström’s macroglobulinemia. / Kastritis, Efstathios; Morel, Pierre; Duhamel, Alain; Gavriatopoulou, Maria; Kyrtsonis, Marie Christine; Durot, Eric; Symeonidis, Argiris; Laribi, Kamel; Hatjiharissi, Evdoxia; Ysebaert, Loic; Vassou, Amalia; Giannakoulas, Nikolaos; Merlini, Giampaolo; Repousis, Panagiotis; Varettoni, Marzia; Michalis, Euridyki; Hivert, Bénédicte; Michail, Michalis; Katodritou, Eirini; Terpos, Evangelos; Leblond, Veronique; Dimopoulos, Meletios A.

In: Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Kastritis, E, Morel, P, Duhamel, A, Gavriatopoulou, M, Kyrtsonis, MC, Durot, E, Symeonidis, A, Laribi, K, Hatjiharissi, E, Ysebaert, L, Vassou, A, Giannakoulas, N, Merlini, G, Repousis, P, Varettoni, M, Michalis, E, Hivert, B, Michail, M, Katodritou, E, Terpos, E, Leblond, V & Dimopoulos, MA 2019, 'A revised international prognostic score system for Waldenström’s macroglobulinemia', Leukemia. https://doi.org/10.1038/s41375-019-0431-y
Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E et al. A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia. 2019 Jan 1. https://doi.org/10.1038/s41375-019-0431-y
Kastritis, Efstathios ; Morel, Pierre ; Duhamel, Alain ; Gavriatopoulou, Maria ; Kyrtsonis, Marie Christine ; Durot, Eric ; Symeonidis, Argiris ; Laribi, Kamel ; Hatjiharissi, Evdoxia ; Ysebaert, Loic ; Vassou, Amalia ; Giannakoulas, Nikolaos ; Merlini, Giampaolo ; Repousis, Panagiotis ; Varettoni, Marzia ; Michalis, Euridyki ; Hivert, Bénédicte ; Michail, Michalis ; Katodritou, Eirini ; Terpos, Evangelos ; Leblond, Veronique ; Dimopoulos, Meletios A. / A revised international prognostic score system for Waldenström’s macroglobulinemia. In: Leukemia. 2019.
@article{e6350fbca0944e00ac07c3f140981be6,
title = "A revised international prognostic score system for Waldenstr{\"o}m’s macroglobulinemia",
abstract = "A staging system was developed a decade ago for patients with Waldenstr{\"o}m’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in the chemoimmunotherapy era. We developed a revised system based on data from 492 symptomatic patients with at least 3 years and a median of 7 years of follow up while an independent validation cohort included 229 symptomatic patients. We identified age (≤65 vs 66–75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin <3.5 gr/dl, and LDH ≥ 250 IU/L (ULN < 225) to stratify patients in five different prognostic groups and identify a very-low risk as well as a very-high risk group with a 3-year WM-related death rate of 0, 10, 14, 38, and 48{\%} (p < 0.001) and 10-year survival rate of 84, 59, 37, 19, and 9{\%} (p < 0.001). We evaluated this staging system separately in patients >65 years and <65 years, according to the reason for initiation of treatment, among patients receiving frontline rituximab or in patients treated primarily without rituximab. With further validation before clinical use, this revised IPSSWM could improve WM patient risk stratification, is easily available and may be used in the everyday practice to provide prognostic information.",
author = "Efstathios Kastritis and Pierre Morel and Alain Duhamel and Maria Gavriatopoulou and Kyrtsonis, {Marie Christine} and Eric Durot and Argiris Symeonidis and Kamel Laribi and Evdoxia Hatjiharissi and Loic Ysebaert and Amalia Vassou and Nikolaos Giannakoulas and Giampaolo Merlini and Panagiotis Repousis and Marzia Varettoni and Euridyki Michalis and B{\'e}n{\'e}dicte Hivert and Michalis Michail and Eirini Katodritou and Evangelos Terpos and Veronique Leblond and Dimopoulos, {Meletios A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41375-019-0431-y",
language = "English",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A revised international prognostic score system for Waldenström’s macroglobulinemia

AU - Kastritis, Efstathios

AU - Morel, Pierre

AU - Duhamel, Alain

AU - Gavriatopoulou, Maria

AU - Kyrtsonis, Marie Christine

AU - Durot, Eric

AU - Symeonidis, Argiris

AU - Laribi, Kamel

AU - Hatjiharissi, Evdoxia

AU - Ysebaert, Loic

AU - Vassou, Amalia

AU - Giannakoulas, Nikolaos

AU - Merlini, Giampaolo

AU - Repousis, Panagiotis

AU - Varettoni, Marzia

AU - Michalis, Euridyki

AU - Hivert, Bénédicte

AU - Michail, Michalis

AU - Katodritou, Eirini

AU - Terpos, Evangelos

AU - Leblond, Veronique

AU - Dimopoulos, Meletios A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in the chemoimmunotherapy era. We developed a revised system based on data from 492 symptomatic patients with at least 3 years and a median of 7 years of follow up while an independent validation cohort included 229 symptomatic patients. We identified age (≤65 vs 66–75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin <3.5 gr/dl, and LDH ≥ 250 IU/L (ULN < 225) to stratify patients in five different prognostic groups and identify a very-low risk as well as a very-high risk group with a 3-year WM-related death rate of 0, 10, 14, 38, and 48% (p < 0.001) and 10-year survival rate of 84, 59, 37, 19, and 9% (p < 0.001). We evaluated this staging system separately in patients >65 years and <65 years, according to the reason for initiation of treatment, among patients receiving frontline rituximab or in patients treated primarily without rituximab. With further validation before clinical use, this revised IPSSWM could improve WM patient risk stratification, is easily available and may be used in the everyday practice to provide prognostic information.

AB - A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in the chemoimmunotherapy era. We developed a revised system based on data from 492 symptomatic patients with at least 3 years and a median of 7 years of follow up while an independent validation cohort included 229 symptomatic patients. We identified age (≤65 vs 66–75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin <3.5 gr/dl, and LDH ≥ 250 IU/L (ULN < 225) to stratify patients in five different prognostic groups and identify a very-low risk as well as a very-high risk group with a 3-year WM-related death rate of 0, 10, 14, 38, and 48% (p < 0.001) and 10-year survival rate of 84, 59, 37, 19, and 9% (p < 0.001). We evaluated this staging system separately in patients >65 years and <65 years, according to the reason for initiation of treatment, among patients receiving frontline rituximab or in patients treated primarily without rituximab. With further validation before clinical use, this revised IPSSWM could improve WM patient risk stratification, is easily available and may be used in the everyday practice to provide prognostic information.

UR - http://www.scopus.com/inward/record.url?scp=85066268709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066268709&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0431-y

DO - 10.1038/s41375-019-0431-y

M3 - Article

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -